SEC Form 4 · accession 0001209191-17-065406
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Brett Primiano
Officer — SVP, OPS, BUS DEV, GC & SEC
Period of report
Dec 11, 2017
Accepted (ET)
Dec 13, 2017 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 11, 2017 | S | 10,042 | $10.8799 | D | 11,381 | D | |
| Common Stock | Dec 12, 2017 | M | 17,000 | $6.54 | A | 28,381 | D | |
| Common StockF3 | Dec 12, 2017 | S | 16,356 | $9.9317 | D | 12,025 | D | |
| Common StockF4 | Dec 12, 2017 | S | 644 | $9.5853 | D | 11,381 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $6.54 | Dec 12, 2017 | M | 17,000 | D | — | Jan 16, 2026 | Common Stock | 17,000 | 23,000 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.68 to $11.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.60 to $10.59, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sale price. These shares were sold in multiple transactions at $9.56 and $9.59. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.